I have to admit, I was skeptical at first. But then I did my homework and reached out to Chase Pharmaceuticals. When the news was released (below) on Sept 7, 2017 stating Dr. Raymond Urbanski, former CMO and senior director of oncology R&D at Pfizer was officially made the new CMO of GT Biopharma, I tried to reach out to MannKind Corporation because I previously bought MannKind around $1 and had researched that company and realized this was the same person. IR returned my and explained to me that on the Sept 11, 2017 8-K filing, they had disclosed this about Dr. Urbanski:
"On September 8, 2017, Raymond W. Urbanski, M.D., Ph.D., our Corporate Vice President, Chief Medical Officer, informed us of his decision to resign his employment with MannKind Corporation, effective September 29, 2017, in order to pursue his passion for oncology at another company."
Previously, OXIS had not wanted to disclose who the former Pfizer CMO was. I was skeptical but now I realize this is because he wanted to be sure the OXIS actually closed the deal and bought out GTP before he made it official his resignation with MannKind. I can appreciate and understand that. I would not give my 2 weeks notice without first confirming employment with my new employers. So, on Sept 7, 2017, OXIS made it official the closing of the deal and hiring of Dr. Urbanski. Dr. Urbanski made it official with MannKind Corporation his resignation on Sept 8, 2017, and this is reflected on MannKind's 8-K.
In other words, OXIS/GT Biopharma is the real deal and not some fly by night scam. They have bought out GTP, acquired Dr. Kathleen as CEO and Dr. Urbanski as CMO, acquired GTP's drugs, one of which is near NDA status, meaning revenue and no more dilution.
So far, they have told us their plans since the summer and they have completed their plans as they promised. The next step is to list on Nasdaq. For all you naysayers, you did not do your homework. You simply shorted and kept scaring investors. If you bothered to do your homework, you will realize that a decent number of companies who are in phase 1, phase 2 and even preclinical gets bought out. Google "HBM Pharma/Biotech M&A Report 2017" and look at the statistics. It's just a matter of time before Dr. Kathleen ensures this company either gets through the FDA or gets bought out for a good sum of money. She is not an idiot and she would not have agreed to let go of her hard earned drugs to OXIS and agreed to the buyout unless she saw a future in this new company. A lot of you question about the worth of the company, but most of you did not even bother doing your homework or even realize what a company like GT Biopharma's true net worth is.
News release from OXIS on Sept 7, 2017 of Dr. Urbanski. Dr. Urbanski promptly reported the next day to his employer, MannKind that he is leaving the company. BTW, he will be with the company until the end of the month. Don't believe me? Reach out to MannKind IR.
LOS ANGELES, CA / ACCESSWIRE / September 7, 2017 / GT Biopharma Inc. (OXISD) announced today the appointment of Dr. Raymond Urbanski, the former business unit Chief Medical Officer and senior director of oncology research and development with Pfizer Inc. (PFE), as its new Chief Medical Officer.
Dr. Urbanski will oversee development of key products in GT Biopharma's product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies as well as its newly acquired Central Nervous System pipeline.
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products.
He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremelimumab.
In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
GT Biopharma Executive Chairman Anthony J. Cataldo said the appointment of Dr. Urbanski as Chief Medical Officer is a key development that comes at an exciting time for the Company.
"We announced on Tuesday the completion of our acquisition/merger of Georgetown Translational Pharmaceuticals, Inc., the elimination of all debt and a suite of neurological products that are late stage and close to market. Along with this, we have retained a world class CEO in Dr. Kathleen Clarence-Smith in the process. Her resume speaks for itself," Mr. Cataldo said.
"Now we complete our executive management team with another world class executive in Dr. Raymond Urbanski as our new CMO. His expertise in oncology assets and quick-to-market 505(b)2 products is timely for GT Biopharma Inc. Ray's big pharma and biotech expertise is custom made for the assets of GT Biopharma. He will be instrumental in helping to guide our highly sought after oncology BiKE and TriKE platform technologies to commercial success. We are excited to have our "Dream Team" in place," Mr. Cataldo said.
Dr. Kathleen Clarence-Smith, Chief Executive Officer of GT Biopharma, said she is pleased that Dr. Urbanski is joining the GT Biopharma team.
